"Your Labs Are Normal." Here's Why That Doesn't Settle Anything.

You finally got the appointment. You described what's been happening — the joints, the heart rate, the flares, the exhaustion, the hormonal chaos — clearly and in detail. The tests came back. Everything's "normal." And you're sitting there knowing something is actually wrong, with a piece of paper that says otherwise.

If that's happened to you more than once, it's not because you're a difficult patient or are bad at explaining your symptoms. For a lot of what shows up in this body type — hypermobility, dysautonomia, mast cell activation, perimenopause — the standard tests were never built to catch it. There's a real, documented gap in how these conditions get diagnosed. Knowing why the testing falls short changes what you ask for next, and what you can reasonably expect medication to do once you get there.

Why the usual workup doesn't always show what's happening

If you have red-flag features — a personal or family history of unexplained aneurysm, artery dissection, or sudden death — genetic testing for rarer Ehlers-Danlos Syndrome (EDS) subtypes is worth pursuing, since those can carry risks hypermobile EDS (hEDS) typically doesn't. But hEDS, the most common type of EDS, doesn't have a genetic test. Researchers still don't know what causes it at the molecular level, which means there's no blood draw or genetic panel that confirms or rules it out. Diagnosis runs entirely on the 2017 clinical criteria instead: a hypermobility score, a set of systemic features (things like stretchy skin, hernias, or dental crowding), and family history — specifically, a first-degree relative who independently meets the same full criteria, not just someone else in the family with loose joints. Genetic testing still has a role, but only to rule other conditions out — not to rule hEDS in. If a provider tells you "your genetic panel was normal, so it's not EDS," that's a misunderstanding of what the panel was checking for. Worth knowing too: a lot of people with real, significant joint symptoms don't clear hEDS's stricter bar and instead land on hypermobility spectrum disorder (HSD) — a related diagnosis with looser criteria, not a less important or less consequential one.

Postural orthostatic tachycardia syndrome (POTS) does have objective testing — a tilt-table test or a simpler active stand test, tracking what your heart rate does when you move from lying to standing. But even here, there's no single universally used protocol. A comprehensive 2026 review defines it as a sustained heart-rate increase of at least 30 beats per minute in adults (40 for adolescents), confirmed on two or more consecutive measurements taken within 10 minutes of standing or head-up tilt, with no significant drop in blood pressure alongside it, at least three months of ongoing symptoms, and only after other causes of a fast heart rate — thyroid disease, anemia, dehydration, certain medications, and several others — have been ruled out. A heart rate that spikes right after standing and then settles back down doesn't meet that bar. Tilt-table and active-stand results don't always match each other, and a test done on a good day can look different from one done on a bad day. So a single normal test doesn't rule POTS out.

Mast cell activation syndrome (MCAS) has the most genuinely contested diagnostic picture of the four. The main lab marker, serum tryptase, has to be drawn in a narrow window — it peaks around an hour after a reaction starts and falls off within a few hours — compared against a baseline drawn after you've fully recovered. Miss that window, which is easy to do when you're in the middle of a reaction and not thinking about lab logistics, and the test won't show what it needed to show. Stricter diagnostic criteria require three things together: at least two documented episodes of severe, typical symptoms across two or more organ systems; a tryptase rise during one of those episodes that clears a specific margin above your own baseline; and symptoms that respond to mast-cell-targeted treatment. Another set of criteria, called Consensus-2, allow for diagnosis without laboratory findings, so it's important to know that this remains up for debate. If you don't meet the stricter criteria, it doesn't mean mast cell activation isn't a part of your picture; it means the test is genuinely harder to catch in the act than most people realize. A tryptase level checked on a calm day won't confirm or rule out MCAS on its own — though if that baseline comes back notably elevated, that's still useful information in its own right, since a persistently high baseline can point toward a separate, related condition (like a hereditary tryptase trait or a mast cell disorder) worth investigating further.

Perimenopause rounds this out, with an age-based catch worth knowing before you interpret any result. FSH and estradiol are the hormones most people ask to have checked, and during the perimenopausal transition — typically starting somewhere in the 40s — both swing widely, sometimes within the same week, rather than declining in a steady line. A single blood draw catches one moment in a pattern that's actively in motion, which is part of why hormone testing generally isn't useful for diagnosing perimenopause itself; it's identified mainly through your cycle and symptom history, not a lab value. One commonly referenced staging framework marks the early transition by a persistent difference of seven days or more in the length of consecutive cycles — though like most thresholds in this space, the exact cutoff isn't something every clinician applies the same way, and cycle tracking is a more useful signal than any single number.

But that's specifically guidance about the perimenopausal transition. If your periods have stopped or gone seriously irregular before age 40, that's a different clinical concern— possibly premature ovarian insufficiency (POI) — and there, FSH testing is more useful. The most current multi-society guideline says one elevated FSH reading (above 25 IU/L), together with at least four months of absent or irregular periods, is enough to diagnose it. That's a change from older guidance — including the version a lot of U.S. practice still runs on — which asked for two elevated FSH readings taken four to six weeks apart before confirming anything. So if your provider asks for a repeat draw, that's not wrong, just an earlier standard.

If the picture is murkier — irregular cycles that could plausibly be POI or could be polyendocrine metabolic ovarian syndrome (PMOS, formerly PCOS) — anti-Müllerian hormone (AMH) can help point one direction or the other: it runs consistently higher in PMOS and tends to run low or undetectable in POI. AMH still isn't a standalone diagnostic marker for either condition on its own — it's one piece of the picture, not a final answer.

What this means once medication enters the conversation

Put those four together and a pattern shows up: for a lot of what you're dealing with, the evidence base guiding diagnosis and treatment decisions is thinner than most people assume.

POTS treatment is the clearest example. Several drugs — beta-blockers, ivabradine, midodrine, and pyridostigmine — have some trial support behind them, though a recent comprehensive review is direct that this support mostly comes from small, short studies, with no large randomized trial yet settling which option works best for whom. Non-drug measures are consistently described as the place to start: 10 to 12 grams of salt (roughly 4 to 5 grams of sodium) plus 2 to 3 liters of fluid a day, and compression somewhere in the 20 to 40 mmHg range that covers the abdomen, not just the legs — a lot of the pooling that drives symptoms happens there, not just below the knee. Those targets assume normal kidney function and aren't automatically the right call for everyone; they're worth confirming with your provider if you have high blood pressure or another cardiovascular condition, where pushing salt and fluid can work against you. If a provider starts there before reaching for a prescription, that's not them brushing you off — that's genuinely where current guidance says to begin.

Medication response itself may also work differently in hypermobile bodies. In one survey of people with EDS, 88% recalled local anesthetic not fully numbing them during a dental procedure, compared to 33% of people without EDS. The researchers themselves call this a patient-reported, "hypothesis-generating" survey, not a controlled trial, so it can't tell us why this happens or confirm it happens at exactly that rate. But it's a documented enough pattern that it's worth mentioning before a dental or minor procedure so your provider can plan for it.

If MCAS and perimenopause overlap for you, hormone therapy decisions get a layer more complicated. There's early laboratory research suggesting estrogen can directly trigger mast cell degranulation. That's a plausible biological thread connecting hormonal shifts to flares, and it may be part of why some people notice their MCAS symptoms moving in step with their cycle or their perimenopausal hormone swings. Estrogen can also affect joint laxity and blood vessel tone. This isn't a reason to avoid hormone therapy; it's a reason to flag the MCAS or hypermobility piece explicitly when that conversation comes up, so formulation and pacing can be considered deliberately.

Bringing this into the appointment

None of this is a reason to stop testing or stop trying medications that might help — it's context for what a given test can and can't tell you, and what a reasonable timeline for finding the right medication actually looks like here. A few things worth carrying into the next appointment: ask what a specific test is actually designed to detect, not just whether it came back normal; if symptoms are intermittent, bring notes on when they happen; and if a medication doesn't work the way it's supposed to, that's data worth reporting.

The bigger picture

The BENDY Method is a 12-week habit-based course for perimenopause and menopause in bodies with hEDS, HSD, MCAS, POTS, dysautonomia, and related presentations. Join the waitlist to be first to know when enrollment opens.

References

  1. HealthEd. Ehlers-Danlos Syndrome – Red Flags for GPs. Clinical education resource for general practitioners, accessed 2026.

  2. Malfait F, Francomano C, Byers P, et al. The 2017 International Classification of the Ehlers-Danlos Syndromes. American Journal of Medical Genetics Part C: Seminars in Medical Genetics. 2017;175(1):8-26.

  3. Forghani I, See J, McGonigle WC. Hypermobile Ehlers-Danlos Syndrome: Diagnostic Challenges and the Role of Genetic Testing. Genes (Basel). 2025;16(5):530.

  4. Chung TH, Raj SR. Postural Orthostatic Tachycardia Syndrome (POTS): A Review. JAMA. 2026;336(13):1149-1164.

  5. Raj SR, Fedorowski A, Sheldon RS. Diagnosis and Management of Postural Orthostatic Tachycardia Syndrome. CMAJ. 2022;194(10):E378-E385.

  6. Gulen T. Using the Right Criteria for MCAS. Current Allergy and Asthma Reports. 2024;24(2):39-51.

  7. Afrin LB, Ackerley MB, Bluestein LS, et al. Diagnosis of Mast Cell Activation Syndrome: A Global "Consensus-2". Diagnosis (Berl). 2020;8(2):137-152.

  8. Valent P, Akin C, Arock M. Reversible Elevation of Tryptase Over the Individual's Baseline: Why Is It the Best Biomarker for Severe Systemic Mast Cell Activation and MCAS? Current Allergy and Asthma Reports. 2024;24(3):133-141.

  9. The Menopause Society (formerly the North American Menopause Society). How Do I Know I'm in Menopause? Patient education page, accessed 2026.

  10. Harlow SD, Gass M, Hall JE, et al.; STRAW+10 Collaborative Group. Executive Summary of the Stages of Reproductive Aging Workshop +10: Addressing the Unfinished Agenda of Staging Reproductive Aging. Fertility and Sterility. 2012;97(4):843-851.

  11. Panay N, Anderson RA, et al. (ESHRE, ASRM, CREW-HIRL and IMS Guideline Group on POI). Evidence-Based Guideline: Premature Ovarian Insufficiency. Fertility and Sterility. 2024.

  12. National Institute for Health and Care Excellence (NICE). Menopause: Diagnosis and Management (NG23) — Information for the Public.

  13. Capuzzo M, La Marca A. Use of AMH in the Differential Diagnosis of Anovulatory Disorders Including PCOS. Frontiers in Endocrinology. 2021;11:616766.

  14. Teede HJ, Khomami MB, Morman R, et al.; Global Name Change Consortium. Polyendocrine Metabolic Ovarian Syndrome, the New Name for Polycystic Ovary Syndrome: A Multistep Global Consensus Process. Lancet. 2026;407(10545):2329-2339.

  15. Olshansky B, Cannom D, Fedorowski A, et al. Postural Orthostatic Tachycardia Syndrome (POTS): A Critical Assessment. Progress in Cardiovascular Diseases. 2020;63(3):263-270.

  16. Dysautonomia International. POTS Treatment Essentials. Patient education resource.

  17. Cumming School of Medicine, University of Calgary. POTS Non-Pharmacological Treatment Guide. Patient education resource, accessed 2026.

  18. Schubart JR, Schaefer E, Janicki P, et al. Resistance to Local Anesthesia in People With the Ehlers-Danlos Syndromes Presenting for Dental Surgery. Journal of Dental Anesthesia and Pain Medicine. 2019;19(5):261-270.

  19. Zierau O, Zenclussen AC, Jensen F. Role of Female Sex Hormones, Estradiol and Progesterone, in Mast Cell Behavior. Frontiers in Immunology. 2012;3:169.

  20. Herzberg SD, Motu'apuaka ML, Lambert W, Fu R, Brady J, Guise JM. The Effect of Menstrual Cycle and Contraceptives on ACL Injuries and Laxity: A Systematic Review and Meta-Analysis. Orthopaedic Journal of Sports Medicine. 2017;5(7).

  21. White RE. Estrogen and Vascular Function. Vascular Pharmacology. 2002;38(2):73-80.

Next
Next

What to Do When Your Nervous System Is Stuck on High Alert